Breaking News Instant updates and real-time market news.

MDT

Medtronic

$73.60

-6.98 (-8.66%)

07:30
11/23/16
11/23
07:30
11/23/16
07:30

Medtronic price target lowered to $88 from $96 at UBS

UBS analyst Matt Miksic lowered his price target on Medtronic to $88 from $96 following Q2 results. The analyst said the company's top-line miss was driven by unrelated and temporary issues and he sees the long-term growth model intact and expects mid-single growth in the second half of 2017. Miksic reiterated his Buy rating on Medtronic shares.

MDT Medtronic
$73.60

-6.98 (-8.66%)

11/14/16
EVER
11/14/16
NO CHANGE
EVER
Medtronic, Edwards Lifesciences defended at Evercore ISI
11/14/16
PIPR
11/14/16
NO CHANGE
PIPR
Overweight
Piper would buy TAVR names on 'GARY' registry weakness
Piper Jaffray analyst Brooks West attributes today's weakness in transcatheter aortic valve replacement makers Medtronic (MDT), Edwards Lifesciences (EW) and Boston Scientific (BSX) to a presentation at the AHA meeting of data from the German Aortic Valve Registry, or "GARY," comparing one year outcomes for patients at intermediate surgical risk who underwent isolated interventional versus conventional surgical aortic valve replacement for severe symptomatic aortic valve stenosis. The data showed a surprisingly negative result, but prior debates around the "GARY" led to no impact on TAVR volumes and West is "skeptical of the results," he tells investors. The firm has Overweight ratings on all three stocks mentioned above.
11/15/16
LEER
11/15/16
NO CHANGE
LEER
Edwards Lifesciences, Medtronic selloff overdone, says Leerink
Leerink analyst Danielle Antalffy notes that both Edwards Lifesciences (EW) and Medtronic (MDT) traded down in reaction to a presentation of the German Aortic Valve Registry data in intermediate risk patients. However, she believes the selloff is overdone, with no change to her estimated total addressable transcatheter aortic valve replacement, or TAVR, market opportunity as there are key baseline characteristic differences between both the surgical valve and TAVR groups that skews the data, and randomized controlled clinical trial data trumps registry data.
11/23/16
JEFF
11/23/16
NO CHANGE
Target $88
JEFF
Buy
Medtronic price target lowered to $88 from $100 at Jefferies
Jefferies analyst Raj Denhoy lowered his price target for Medtronic to $88 saying the "weak" Q2 set back almost a year of progress for the company. "The recent strong product cycles have waned and the company finds itself in a slower period before new things kick in," Denhoy tells investors in a post-earnings research note. The analyst keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.